title: [Adjuvant chemotherapy with FOLFOX4 regimen after curative resection of liver metastases from colorectal cancer].
abstract: Only a partial benefit of adjuvant chemotherapy administered after curative resection of colorectal cancer (CRC) metastases has been demonstrated. We report here our experience of 7 cases that were administered FOLFOX4 regimen as adjuvant chemotherapy after a curative resection of liver metastases from CRC. Five patients received 6 cycles of FOLFOX4 after prophylactic hepatic arterial infusion of 5-FU, and 2 remaining patients simply received 8 cycles of FOLFOX4. All patients completed the planned cycles of FOLFOX4 without any dose reduction of oxaliplatin. No patients developed a severe adverse effect greater than grade 2 except for grade 3 neutropenia observed in 4 cases. Although lung metastases occurred in 2 cases 28.1 and 21.3 months after liver resection, respectively, all patients are alive after a median follow up of 23.5 months. Our experience indicates that adjuvant chemotherapy with six to eight cycles of FOLFOX4 regimen is safe with a high dose intensity of oxaliplatin and expected to provide a survival benefit.
authors.affiliation: Dept. of Surgery, NTT West Osaka Hospital.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ohnishi
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kanoh
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tono
authors.forename: Katsuki
authors.initials: K
authors.lastname: Danno
authors.forename: Ami
authors.initials: A
authors.lastname: Watanabe
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Nakamura
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Tsukao
authors.forename: Junichi
authors.initials: J
authors.lastname: Inatome
authors.forename: Tiwan
authors.initials: T
authors.lastname: Kim
authors.forename: Naofumi
authors.initials: N
authors.lastname: Kagara
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Nakano
authors.forename: Takushi
authors.initials: T
authors.lastname: Monden
authors.forename: Shingi
authors.initials: S
authors.lastname: Imaoka
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000556:secondary* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil